EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

The Growing Role of Glucagon-Like Peptide-1 Receptor Agonists in Neuropsychiatry

Ece Buyuksandalyaci Tunc iD, Mary Park, Rudra Kansara, Shristi Paul, Noam Grysman, George T Grossberg

Clinical Pharmacology: Advances and Applications · 2026-11 · Volume 18 · 1-27

DOI: 10.2147/cpaa.s580850 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Pharmacology: Advances and Applications, 2026-11. Verfasst von Ece Buyuksandalyaci Tunc und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Geriatric Psychiatry, Department of Psychiatry and Behavioral Neuroscience, Saint Louis University School of Medicine, St. Louis, MO, USA. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The co-occurrence of metabolic and psychiatric disorders poses a major challenge in medicine, and glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as candidates for neuropsychiatric repurposing given the wide distribution of glucagon-like peptide-1 (GLP-1) receptors in brain regions governing mood, cognition, and reward. This narrative review summarizes central and peripheral mechanisms linking GLP-1 signaling to neuropsychiatric outcomes, critically appraises clinical evidence across psychiatric and neurodegenerative domains, and proposes a framework for integrating GLP-1RAs into neuropsychiatric care. A targeted search of PubMed/MEDLINE and ClinicalTrials.gov (January 2015-August 2026) prioritized randomized controlled trials, meta-analyses, and prospective cohorts reporting neuropsychiatric outcomes. Four converging mechanisms- neuroinflammation, metabolic-vascular neuroprotection, synaptic plasticity, and mesolimbic reward modulation- underpin this rationale. The strongest and most clinically actionable evidence supports GLP-1RA use for antipsychotic-induced metabolic dysfunction, with trials in clozapine/olanzapine-treated patients showing substantial weight loss and glycemic normalization without psychiatric worsening or altered clozapine levels. By contrast, in Alzheimer’s disease, despite consistent observational signals of 33– 53% dementia risk reduction, Phase 3 EVOKE/EVOKE+ trials found no benefit of oral semaglutide in early symptomatic disease despite biomarker engagement, favoring a prevention- rather than treatment-focused framework. Evidence in Parkinson’s disease and major depressive disorder remains more limited: motor benefit in Parkinson’s disease appears restricted to short-acting agents, with the largest phase 3 trial negative, while broad antidepressant efficacy is unsupported, although semaglutide improved effort-based decision-making in anhedonic, metabolically burdened patients. Additional signals exist for alcohol use disorder, binge eating disorder, and obstructive sleep apnea. Psychiatric safety appears reassuring across meta-analyses of over 133,000 participants, though exclusion of psychiatric populations from pivotal trials limits generalizability. Current evidence supports selective, investigational use of GLP-1RAs in neuropsychiatric care- most robustly for antipsychotic-induced metabolic dysfunction- rather than generalized repurposing, pending adequately powered trials with neuropsychiatric endpoints, structured monitoring, and equitable access strategies. Keywords: glucagon-like peptide-1 receptor agonists, semaglutide, mental disorders, antipsychotics, Alzheimer disease, substance-related disorders, metabolic syndrome, neuroinflammation

Schlagwörter

Stichwörter der Autor:innen

Alzheimer diseaseantipsychoticsglucagon-like peptide-1 receptor agonistsmental disordersmetabolic syndromeneuroinflammationsemaglutidesubstance-related disorders

Autor:innen und Institutionen

  • Division of Geriatric Psychiatry, Department of Psychiatry and Behavioral Neuroscience, Saint Louis University School of Medicine, St. Louis, MO, USA.

ORCID-Profile: Ece Buyuksandalyaci Tunc

Zitieren

APA

Buyuksandalyaci Tunc, E., Park, M., Kansara, R., Paul, S., Grysman, N., & Grossberg, G. T. (2026). The Growing Role of Glucagon-Like Peptide-1 Receptor Agonists in Neuropsychiatry. Clinical Pharmacology: Advances and Applications, Volume 18, 1-27. https://doi.org/10.2147/cpaa.s580850

Vancouver

Buyuksandalyaci Tunc E, Park M, Kansara R, Paul S, Grysman N, Grossberg GT. The Growing Role of Glucagon-Like Peptide-1 Receptor Agonists in Neuropsychiatry. Clinical Pharmacology: Advances and Applications. 2026;Volume 18:1-27. doi:10.2147/cpaa.s580850

BibTeX
@article{BuyuksandalyaciTunc2026,
  author = {Buyuksandalyaci Tunc, Ece and Park, Mary and Kansara, Rudra and Paul, Shristi and Grysman, Noam and Grossberg, George T},
  title = {The Growing Role of Glucagon-Like Peptide-1 Receptor Agonists in Neuropsychiatry},
  journal = {Clinical Pharmacology: Advances and Applications},
  year = {2026},
  volume = {Volume 18},
  pages = {1--27},
  doi = {10.2147/cpaa.s580850}
}
Kostenlos starten →